Samsung Galaxy S4
Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury's previous verdict. The jury determined Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.